{"filings":[{"id":805840,"accession_number":"0001140361-26-023705","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-06-02T20:05:29+00:00","items":["5.07"],"status":"ready","headline":"ADMA Biologics annual meeting results: all proposals pass including election of two Class I directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Alison C. Finger elected as Class I director with 156.8M for, 19.4M withheld, 23.0M broker non-votes.","Eduardo Rene Salas elected with 172.0M for, 4.3M withheld, 23.0M broker non-votes.","Ratification of KPMG as auditor for FY2026 approved: 198.7M for, 0.33M against, 0.28M abstain.","Non-binding Say-on-Pay proposal approved with 168.2M for, 7.7M against, 0.33M abstain, 23.0M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92449,"accession_number":"0001140361-26-019295","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Q1 revenue flat at $114.5M, ASCENIV up 28%; withdraws long-term guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $114.5M flat YoY; ASCENIV rev $97.5M (+28%) offset by BIVIGAM -54%.","GAAP net income $45.3M (+68%); Adjusted net income $40.7M (+22%); Adjusted EBITDA $59.7M (+24%).","FY 2026 guidance: rev $530-560M, Adj EBITDA $265-300M; withdraws long-term guidance due to market dynamics.","Audit committee review found no improper channel stuffing or undisclosed related-party transactions.","Cash from ops $58M; gross margin expanded to 71% from 53% on product mix shift."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":114493000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92448,"accession_number":"0001140361-26-018667","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics receives FDA approval to expand ASCENIV label to pediatric patients 2 years+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved label expansion for ASCENIV to include pediatric primary humoral immunodeficiency patients aged 2 years and older.","Previously approved only for patients 12 years and older; approval fulfills post-marketing pediatric assessment commitment.","CEO Adam Grossman: expanded label allows addressing treatment needs of younger PI patients earlier in their treatment journey.","COO Kaitlin Kestenberg highlighted collaboration with PI community and families; approval reflects strong clinical execution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103293,"accession_number":"0001140361-26-011569","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics refutes Culper Research short seller allegations; provides inventory & demand data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Demand for ASCENIV growing; end-user demand increased past two years; current days on hand average 90 days as of March 22, 2026.","Refutes channel stuffing; says distributor inventory levels consistent with industry standards; average days on hand above safety stock: 48 days for ASCENIV, 51 days for BIVIGAM as of March 22.","ASCENIV positioned as late-line therapy for immune compromised patients who fail standard IG; premium pricing; new IVIG launches not competitive threat.","ADMA received unqualified audit opinions from Big Four firm for FY2024 and FY2025; prior auditor resigned due to acquisition.","No undisclosed related party transactions; no Grossman-family entity distributed or took title to any ADMA products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103292,"accession_number":"0001140361-26-007230","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.","Total 2026 share repurchase initiative target is ~$200M, funded via existing $225M revolving credit facility.","Since program authorization in May 2025, ~$160M of common stock repurchased to date.","CEO states stock is \"meaningfully undervalued\" relative to business strength and growth trajectory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103291,"accession_number":"0001140361-26-006781","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"ADMA Biologics reports record FY2025 revenue $510M (+20%), Adj. EBITDA $231M (+40%); CFO transition to Kohler","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 total revenue $510.2M (+20% YoY); ASCENIV revenue $363M (+51% YoY). Gross margin 57.4% vs 51.5%.","GAAP net income $146.9M (FY2024: $197.7M incl. $84.3M tax benefit). Adjusted net income $160.8M (+35% YoY). Adjusted EBITDA $231M (+40%).","FY2026 guidance: revenue >$635M, Adj. net income >$255M, Adj. EBITDA >$360M. Targeting >$1.1B revenue by FY2029.","CFO Brad Tade retiring effective Feb 25, 2026; succeeded by Terry Kohler (ex-CFO of OptiNose, Verrica). Kohler will become CFO/Treasurer Feb 26.","Q4 2025: revenue $139.2M (+18% YoY); GAAP net income $49.4M; Adj. EBITDA $73.6M (+52% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":510173000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103290,"accession_number":"0001140361-26-000906","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADMA prelim FY2025 rev ~$510-511M, raises FY2026 rev/EBITDA guidance, targets >$1.1B by 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary FY2025 total revenue ~$510-511M, meeting or exceeding prior guidance. Cash grew to ~$88M with ~$40M Q4 operating cash flow.","FY2026 revenue guidance raised to ~$635M (from $630M); FY2026 adjusted EBITDA raised to ~$360M (from $355M). Adjusted net income reiterated at ~$255M.","FY2027 revenue guided ~$775M, adjusted net income ~$315M, adjusted EBITDA ~$455M.","Long-term targets: >$1.1B revenue and >$700M adjusted EBITDA by FY2029. Yield-enhanced production now routine, 2026 first full year of monetization.","Divested three plasma centers for $12M, secured long-term supply agreements, expects accretive cost savings from strategic repositioning."],"consensus_eps_estimate":null,"consensus_eps_actual":0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":510173000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119545,"accession_number":"0001140361-25-040539","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).","Revenue guidance raised: FY25 to ≥$510M (from >$500M); FY26 to ≥$630M (from >$625M).","Adj EBITDA guidance: FY25 reaffirmed at $235M; FY26 raised to >$355M (from >$340M).","FDA lot release of first yield-enhanced batches; gross margin expansion expected from Q4 2025.","Record ASCENIV demand; real-world data shows >50% infection reduction (2.1→0.9/year)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":371010000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136113,"accession_number":"0001140361-25-029143","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["1.01","1.02","2.02","2.03","9.01"],"status":"ready","headline":"ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).","GAAP net income $34.2M; Adjusted EBITDA $50.8M, up 59% YoY underlying.","Began commercial-scale yield-enhanced IG manufacturing delivering 20%+ output gain.","Closed $300M J.P. Morgan-led financing ($75M term loan, $225M revolver) replacing Ares debt.","Reaffirmed FY2025-2026 guidance; pre-2030 revenue target $1.1B+; repurchased $15M stock."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":236786000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153161,"accession_number":"0001140361-25-021440","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ADMA Biologics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jerrold B. Grossman elected with 165.1M votes for, 16.5M withheld; 23.4M broker non-votes.","Lawrence P. Guiheen elected with 133.8M for, 47.8M withheld; 23.4M broker non-votes.","Ratification of KPMG as auditor: 204.6M for, 269,649 against, 127,057 abstain.","Non-binding say-on-pay approved: 161.5M for, 19.9M against, 266,852 abstain; 23.4M broker non-votes.","Shareholders favored 1-year frequency for future say-on-pay votes (173.1M votes for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153160,"accession_number":"0001140361-25-017704","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).","FY2025 revenue guidance raised to >$500M; FY2026 to >$625M; adjusted EBITDA guidance >$235M and >$340M, respectively.","Board authorized $500M share repurchase program (~8% of market cap); timing and amount discretionary.","Debt reorganized: $30M borrowed on revolver to repay term loan; revolver outstanding $72.5M, term loan $2.5M; cost of debt down 1.1%.","FDA-approved yield enhancement process expected to increase IG output 20% from same plasma volume, supporting future growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":114802000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153159,"accession_number":"0001140361-25-015881","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics receives FDA approval for yield enhancement process; expects ~20% output increase","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved innovative production yield enhancement process increasing yields by ~20% from same plasma volume.","Approval applies to both immune globulin products ASCENIV and BIVIGAM.","CEO anticipates revenue and earnings acceleration beginning late 2025 and accelerating into 2026.","First U.S. regulatory approval for such a process; highlights ADMA's internal R&D and capital efficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171945,"accession_number":"0001140361-25-006745","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).","Q4 2024 revenue $117.5M (+59% YoY); GAAP net income $111.9M vs net loss of $17.6M; Adjusted EBITDA $48.3M vs $18.6M.","FY 2025 revenue guidance raised to >$490M; FY 2026 >$605M; expects >$1B total revenue before 2030.","FDA approval of yield enhancement process expected mid-2025, potentially increasing IG yields ~20%; long-term plasma supply from ~250 centers.","Form 10-K filing delayed to on or before March 18, 2025 due to need for additional time to test internal controls with KPMG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171944,"accession_number":"0001140361-25-005489","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics sets 2025 executive comp; CEO Grossman base $925k with equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Grossman: 2025 base $925k, 2024 cash bonus $1.02M, 252,022 RSUs, 376,744 options at $16.07 strike.","COO Kestenberg: 2025 base $575k, 2024 bonus $293,625, 77,784 RSUs, 116,279 options.","CFO Tade: 2025 base $500k, 2024 bonus $254,475, 62,227 RSUs, 93,023 options.","Non-employee directors get annual equity grants of $350k (50% RSUs, 50% options) and increased committee retainers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171943,"accession_number":"0001140361-25-000871","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics furnishes January 2025 corporate presentation without material updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation furnished under Regulation FD; no specific financial results or guidance changes disclosed.","Presentation expected to be used in meetings with investors, analysts, and strategic partners.","Exhibit contains only a title slide; no operational or strategic updates provided.","Company makes no admission as to materiality of information furnished."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171942,"accession_number":"0001140361-25-000870","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.","FY2025 revenue guided >$485M, net income >$170M, Adj EBITDA >$220M; FY2026 revenue >$600M, net income >$230M.","PAS submitted to FDA for yield enhancement process that could increase IG yields ~20%; approval expected mid-2025.","Executed long-term high titer plasma supply contracts from ~250 collection centers (5x increase) to support ASCENIV growth.","Balance sheet: net cash surplus vs. $75M debt; expect >$1B annual revenue before 2030 with outsized earnings growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":426454000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171941,"accession_number":"0001140361-25-000073","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics appoints Eduardo Rene Salas to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Eduardo Rene Salas as Class I director, term expiring at 2026 annual meeting.","Salas is former EY audit partner (2002-2019) and former CFO of Wellstat Therapeutics (2020-2022).","He currently serves on audit committee of Intra-Cellular Therapies (since 2022).","He will receive initial grant of options to purchase 20,011 shares of common stock.","No material transactions or arrangements in connection with appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188943,"accession_number":"0001140361-24-050002","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA Biologics repays $30M of senior secured term loan, total debt reduced to $75M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $30M of original $62.5M term loan with Ares Capital using cash on hand.","Total gross debt now $75M: $42.5M revolver plus $32.5M term loan outstanding.","This is second paydown in four months; total gross debt reduced by 29%.","Lowered interest expense expected to enhance near-term earnings growth potential.","CEO cites confidence in sustained earnings growth and ongoing cash generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188942,"accession_number":"0001140361-24-047487","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics board member Bryant Fong resigns; committee chairs reassigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryant Fong resigned from board effective Nov 19, 2024 to focus on other roles; no disagreements.","Young T. Kwon appointed Chairman of Audit Committee and designated audit committee financial expert.","Steven A. Elms added to Audit Committee.","Alison C. Finger added to Governance and Nominations Committee and Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188941,"accession_number":"0001140361-24-045657","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q3 total revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%); Adj. EBITDA $45.4M (+256%)","FY2024 guidance raised: revenue >$415M (from >$400M), GAAP net income >$120M (from >$105M), Adj. EBITDA >$160M (from >$150M)","FY2025 guidance raised: revenue >$465M, net income >$165M, Adj. EBITDA >$215M","Appointed KPMG as new independent registered public accounting firm, replacing CohnReznick after 17 years","ASCENIV now >50% of revenue; sBLA filing planned for label expansion; pediatric study database lock in Q4 2024"],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":308905000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188940,"accession_number":"0001140361-24-044808","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ADMA Biologics engages KPMG as new auditor effective after Q3 2024 10-Q filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KPMG appointed as independent registered public accounting firm on October 31, 2024, effective upon filing of Q3 2024 10-Q.","No consultations or disagreements with KPMG during prior fiscal years 2022-2023 and interim period through October 31, 2024.","KPMG will audit the consolidated financial statements for FY 2024, expected to be filed by March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188939,"accession_number":"0001140361-24-043250","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics affirms 2024-2025 guidance unaffected by auditor switch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Management stated no anticipated impact to previously provided 2024-2025 financial guidance from auditor transition.","Statement made after market close on Oct 9, 2024, in discussions with analysts.","Auditor change described in separate Form 8-K filed on Oct 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188938,"accession_number":"0001140361-24-043222","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ADMA Biologics auditor CohnReznick resigning effective after Q3 2024 filing; audit committee seeking replacement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CohnReznick LLP notified ADMA of resignation as independent auditor effective after filing of Q3 2024 10-Q.","No disagreements or reportable events during fiscal years 2022 and 2023 or subsequent interim period.","Audit Committee initiated process to select new auditor for FY 2024 audit and internal control over financial reporting.","CohnReznick's reports on FY 2023 and 2022 financials were unqualified, no adverse opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205415,"accession_number":"0001140361-24-037184","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADMA repays $30M of revolver; total debt reduced to $105M, a 22% reduction","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $30M from $72.5M Ares Capital revolver with no prepayment penalties.","Total gross debt reduced to $105M ($62.5M term loan + $42.5M revolver).","Paydown funded from cash on hand generated organically.","Lower interest expense expected to enhance earnings growth.","Company expects further reduction and optimization of capital costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205414,"accession_number":"0001140361-24-036399","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.","Adjusted EBITDA $44.5M, up ~592% YoY; gross margin improved to 53.6% from 27.8%.","FY2024 revenue guidance raised to >$400M (from >$355M); FY2025 revenue >$445M (from >$410M).","FY2024 GAAP net income guidance raised to >$105M; adjusted EBITDA guidance >$150M.","Commercial-scale yield enhancement of ~20% from same starting plasma; potential benefit as early as Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":189066000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205413,"accession_number":"0001140361-24-034440","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics promotes Brad Tade to CFO and Treasurer, effective July 24, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Tade, former VP Financial Operations, promoted to CFO and Treasurer effective July 24, 2024.","Base salary set at $435,000 annually; target bonus of 45% of base salary.","Granted 115,100 stock options and 72,400 RSUs, each vesting over four years.","Severance includes 12 months base salary; 15 months plus 1.5x target bonus if within one year of change of control.","Tade joined ADMA in June 2023; prior roles at Baxter International and Becton Dickinson."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222324,"accession_number":"0001140361-24-031778","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ADMA Biologics amends bylaws to reduce director removal threshold to majority vote and add exclusive forum provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduced director removal with cause threshold from 66 2/3% to a majority of voting holders.","Added exclusive forum provision requiring internal corporate suits be brought in Delaware courts.","Added federal forum selection clause for Securities Act claims unless company consents otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222323,"accession_number":"0001140361-24-028800","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADMA Biologics shareholders elect three Class II directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Steven A. Elms, Adam S. Grossman, Young T. Kwon elected as Class II directors with 71%, 97%, 98% of votes cast excluding broker non-votes.","Ratification of CohnReznick LLP as independent auditor for FY2024 approved with 184.5M for, 2.0M against, 0.2M abstain.","Annual meeting quorum achieved with 186.7M shares represented out of 231.8M outstanding (80.5% of shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222322,"accession_number":"0001140361-24-026601","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADMA Biologics posts May 2024 corporate presentation; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation titled 'Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology' made available.","Presentation intended for use in discussions with potential investors, strategic partners, and analysts.","No new financial guidance, product milestones, or material operational changes were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222321,"accession_number":"0001140361-24-025173","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADMA Biologics Q1 revenue $81.9M (+44% YoY); raises FY2024-25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $17.8M vs net loss of $6.8M in prior year; adjusted EBITDA $26.4M, a 970% increase.","Gross margin improved to 48% from 29% YoY; working capital $223.3M, cash $45.3M.","FY2024 revenue guidance raised to >$355M (prior >$330M); net income >$85M (prior >$65M).","FY2025 revenue guidance raised to >$410M; adjusted EBITDA >$160M, up from >$140M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":81875000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222320,"accession_number":"0001140361-24-017331","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADMA Biologics promotes Kaitlin Kestenberg to COO and SVP, Compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kestenberg promoted from SVP, Compliance & Project Operations to COO and SVP, Compliance, effective April 1, 2024.","Base salary of $460,000; annual target bonus of 50% of base salary.","Granted options for 300,328 shares and 192,320 RSUs, each vesting over four years.","Severance includes 12 months salary (or 15 months plus 1.5x bonus upon change of control) plus COBRA.","Kestenberg has been with ADMA since 2011; prior roles at Acorda Therapeutics and Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241847,"accession_number":"0001140361-24-012605","cik":1368514,"company_name":"ADMA BIOLOGICS, INC.","ticker":"ADMA","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves extended room temperature storage for ADMA's ASCENIV and BIVIGAM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved supplemental BLAs to allow 4-week room temperature (25°C) storage at any time during the 36-month shelf life.","Previously, room temperature storage was only allowed during the first 24 months; now applies to all existing and future lots.","CEO Adam Grossman stated the approval enables reaching customers previously limited by cold chain constraints.","Both products are immediately commercially available to U.S. healthcare providers.","Approval expected to improve inventory management and product administration for providers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1855340644.421086,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}